Shares of AngioDynamics ANGO remained unaffected after the company reported Q1 results.
Quarterly Results
Earnings per share fell 75.00% over the past year to $0.02, which beat the estimate of ($0.07).
Revenue of $70,216,000 higher by 6.32% year over year, which beat the estimate of $65,100,000.
Looking Ahead
AngioDynamics said it sees FY21 EPS of $0.00-0.05 and sales of $278 million to $284 million.
Conference Call Details
Date: Sep 29, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/i2jd82xi
Price Action
52-week high: $18.70
52-week low: $7.48
Price action over last quarter: Up 12.85%
Company Description
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
